Hartford Investment Management Co. Sells 1,431 Shares of Humana Inc. (NYSE:HUM)

Hartford Investment Management Co. lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 14.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,299 shares of the insurance provider’s stock after selling 1,431 shares during the period. Hartford Investment Management Co.’s holdings in Humana were worth $3,799,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in Humana in the 4th quarter worth about $690,516,000. Starboard Value LP bought a new position in Humana in the 1st quarter worth about $421,332,000. Ameriprise Financial Inc. boosted its stake in Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after purchasing an additional 402,559 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Humana in the 1st quarter worth about $151,766,000. Finally, Morgan Stanley boosted its stake in Humana by 20.8% in the 4th quarter. Morgan Stanley now owns 1,688,442 shares of the insurance provider’s stock worth $864,804,000 after purchasing an additional 290,865 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the purchase, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Price Performance

HUM traded up $3.98 during trading on Thursday, hitting $312.04. 794,308 shares of the company traded hands, compared to its average volume of 2,096,501. The company has a market cap of $37.65 billion, a PE ratio of 15.63, a P/E/G ratio of 1.79 and a beta of 0.45. The stock’s 50-day simple moving average is $354.91 and its two-hundred day simple moving average is $437.79. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63.

Humana (NYSE:HUM) last posted its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $26.46 billion for the quarter, compared to analysts’ expectations of $25.47 billion. During the same period in the previous year, the business posted $1.62 earnings per share. The business’s revenue was up 17.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Humana Inc. will post 16.02 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be paid a $0.885 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.13%. Humana’s payout ratio is currently 17.86%.

Analyst Ratings Changes

HUM has been the topic of a number of analyst reports. TD Cowen dropped their price target on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research note on Tuesday. Mizuho decreased their price target on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. Bank of America reiterated a “neutral” rating and issued a $342.00 price target (down from $470.00) on shares of Humana in a research report on Tuesday. Oppenheimer restated an “outperform” rating and set a $630.00 price objective on shares of Humana in a research report on Wednesday, January 17th. Finally, Truist Financial restated a “hold” rating and set a $550.00 price objective on shares of Humana in a research report on Friday, January 19th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $468.74.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.